Abstract | BACKGROUND: Ependymal tumors in adults are rare, accounting for less than 4% of primary tumors of the central nervous system in this age group. The low prevalence of intracranial ependymoma in adults limits the ability to perform clinical trials. Therefore, treatment decisions are based on small, mostly retrospective studies and the role of chemotherapy has remained unclear. METHODS: We performed a retrospective study on 17 adult patients diagnosed with intracranial World Health Organisation grade II or III ependymoma, who were treated with chemotherapy at any time during the disease course. Benefit from chemotherapy was estimated by applying Macdonald criteria. Progression-free (PFS) and overall survival (OS) were calculated from start of chemotherapy, using the Kaplan-Meier method. RESULTS: CONCLUSIONS:
|
Authors | Dorothee Gramatzki, Patrick Roth, Jörg Felsberg, Silvia Hofer, Elisabeth J Rushing, Bettina Hentschel, Manfred Westphal, Dietmar Krex, Matthias Simon, Oliver Schnell, Wolfgang Wick, Guido Reifenberger, Michael Weller |
Journal | BMC cancer
(BMC Cancer)
Vol. 16
Pg. 287
(Apr 23 2016)
ISSN: 1471-2407 [Electronic] England |
PMID | 27108407
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Procarbazine
- Epirubicin
- Vincristine
- Lomustine
- Dacarbazine
- Ifosfamide
- Temozolomide
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Brain Neoplasms
(drug therapy, pathology)
- Dacarbazine
(administration & dosage, analogs & derivatives)
- Disease-Free Survival
- Ependymoma
(drug therapy, pathology)
- Epirubicin
(administration & dosage)
- Female
- Humans
- Ifosfamide
(administration & dosage)
- Kaplan-Meier Estimate
- Lomustine
(administration & dosage)
- Male
- Middle Aged
- Procarbazine
(administration & dosage)
- Temozolomide
- Treatment Outcome
- Vincristine
(administration & dosage)
|